35 / 45
Atezolizumab and chemotherapy
Schmid P, et al. IMpassion130
ESMO 2018 (LBA1_PR)
http://bit.ly/2DMhaygDC, dendritic cell.
1. Chen
Immunity
2013. 2. Zitvogel
Immunity
2013. 3. Emens
CIR
2015. 4. TECENTRIQ US PI/SmPC 2018. 5. Herbst
Nature
2014.
6. Emens
JAMA Oncol
2018. 7. Jotte ASCO 2018. 8. Pohlmann AACR 2018.
Chemotherapy:
Promotes DC
recruitment to the
site of cell death
2,3
Atezolizumab:
Restores anti-cancer immunity,
1
with
activity further enhanced by chemotherapy-induced antigen
exposure
Atezolizumab:
Promotes T-cell
activation
1
Tumour
cells
DC
Activated
T cells
Tumour
antigens
•
Atezolizumab (anti–PD-L1) monotherapy is
approved in the United States, Europe and
elsewhere for certain types of metastatic urothelial
carcinoma and lung cancer
4
•
In a Phase I study, atezolizumab monotherapy
was active in multiple cancers, including TNBC,
5,6
with greater activity in patients whose tumours
had PD-L1 IC ≥ 1%
6
•
The addition of chemotherapy can enhance
atezolizumab’s anti-tumour activity
7,8
•
In a Phase Ib study in mTNBC,
concurrent administration of
nab
-
paclitaxel did not inhibit
atezolizumab-mediated
immunodynamic effects
8